Breaking News

Ligand, Spectrum Sign Global Supply Pact

March 14, 2013

Licenses melphalan product for development program

Ligand Pharmaceuticals has signed a global license and supply agreement with Spectrum Pharmaceuticals for the development and commercialization of Ligand’s Captisol-enabled, propylene glycol-free (PG-free) melphalan. Ligand is entitled to receive a license fee and is eligible to receive more than $50 million in potential milestones, as well as royalties on future sales of Captisol-enabled melphalan.
The Captisol-enabled melphalan program is currently in development for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Spectrum will assume all development of the program under the license.
“We are pleased to have forged this agreement,” said John Higgins, president and chief executive officer of Ligand Pharmaceuticals. “Spectrum has an established oncology and hematology business, and this melphalan product is an ideal complement to their two commercial hematology products, Zevalin and Folotyn, including an expected high degree of commercial call overlap. Spectrum’s highly experienced, oncology-focused R&D team is committed to the efficient development of Captisol-enabled melphalan, and has established relationships with key investigators.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks